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Background: The capacity of patient’s Natural Killer cells (NKs) to be activated for cytolysis is an important
prerequisite for the success of antibody-derived agents such as single-chain triplebodies (triplebodies) in cancer
therapy. NKs recovered from AML patients at diagnosis are often found to be reduced in peripheral blood titers
and cytolytic activity. Here, we had the unique opportunity to compare blood titers and cytolytic function of NKs
from an AML patient with those of a healthy monozygotic twin. The sibling’s NKs were compared with the patient’s
drawn either at diagnosis or in remission after chemotherapy. The cytolytic activities of NKs from these different
sources for the patient’s autologous AML blasts and other leukemic target cells in conjunction with triplebody
SPM-2, targeting the surface antigens CD33 and CD123 on the AML cells, were compared.
Methods: Patient NKs drawn at diagnosis were compared to NKs drawn in remission after chemotherapy and a
sibling’s NKs, all prepared from PBMCs by immunomagnetic beads (MACS). Redirected lysis (RDL) assays using
SPM-2 and antibody-dependent cellular cytotoxicity (ADCC) assays using the therapeutic antibody RituximabTM
were performed with the enriched NKs. In addition, MACS-sorted NKs were analyzed for NK cell activating receptors
(NCRs) by flow cytometry, and the release of TNF-alpha and IFN-gamma from blood samples of both siblings after
the addition of the triplebody were measured in ELISA-assays.
Results: Patient NKs isolated from peripheral blood drawn in remission produced comparable lysis as NKs from the
healthy twin against the patient’s autologous bone marrow (BM) blasts, mediated by SPM-2. The NCR receptor
expression profiles on NKs from patient and twin were similar, but NK cell titers in peripheral blood were lower for
samples drawn at diagnosis than in remission.
Conclusions: Peripheral blood NK titers and ex vivo cytolytic activities mediated by triplebody SPM-2 were comparable
for cells drawn from an AML patient in remission and a healthy twin. If these results can be generalized, then NKs from
AML patients in remission are sufficient in numbers and cytolytic activity to make triplebodies promising new agents
for the treatment of AML.
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Interest in the development of antibodies and antibody-
derived agents such as antibody-drug conjugates (ADCs) and
bispecific agents for the treatment of acute myeloid leukemia
(AML) has increased over the past years. A prototypical
agent, gemtuzumab ozogamycin (GO; MylotargTM), has been
effective in the treatment of AML, but was withdrawn from
the market because of side toxicities [1,2]. The problem
causing this withdrawal was not related to the suitability of
the myeloid surface antigen CD33 as a target, but rather to
the chemical linker connecting the toxin component of this
drug to the antibody carrier. CD33 remains a valuable and
clinically validated target for the therapy of CD33-positive
subtypes of AML with antibody-derived agents [3-5], and
consequently, several major drug developers currently study
new agents for the treatment of AML with specificity for
CD33. One class of such agents relies on potent new toxins
coupled with improved linkers to the antibody, such as the
agent SGN-CD33a [6]. Another class recruits effector cells
including NKs or T cells for the elimination of AML cells.
This class includes the agent AMG-330 [7] recruiting Tcells
as effectors, as well as our team’s single chain triplebodies
123-16-33 [8] and 33-16-33 [9], recruiting NKs. It
further includes CD33-specific antibodies with Fc domains
engineered for improved binding to Fc-receptors on
effector cells. Also, antibodies specific for CD123, the alpha
subunit of the receptor for Interleukin-3, an important
growth and differentiation factor for early hematopoietic
cells and the myeloid lineage, have produced promising
results in preclinical studies [10]. Antibodies against CD123
have mediated cytolysis of AML cells and in particular of
AML-Leukemia Stem Cells (AML-LSCs) [11,12].
Our team has developed a new class of antibody-
derived fusion proteins called triplebodies, suited for
the elimination of AML cells [8,9,13-17]. These agents
carry two binding sites for surface antigens on the
cancer cell and one for a trigger molecule on an effector
cell. They can bind two different tumor antigens on
the same target cell and through this mode of “dual
targeting” address the cancer cell with enhanced selectivity
[15,16,18]. In addition, they bind a trigger molecule on an
effector cell, such as CD16 on NKs, and thereby activate
the effector for cytolytic elimination of the cancer cell.
Triplebody SPM-2 employed in the present study carries
single chain Fv (scFv) antibody fragments specific for
CD33 and CD123 on AML cells linked in a single poly-
peptide chain to an scFv module specific for CD16,
the low affinity Fc gamma RIII receptor on NKs and
macrophages and a few other cells of the hematopoietic
system [8]. SPM-2 was designed for the elimination of
both bulk AML cells and AML-LSCs, because both are
double-positive for this pair of antigens.
LSCs from patients with most subtypes of AML however
carry a higher combined cell surface density of this pair ofantigens than bulk AML cells, normal hematopoietic cells,
and healthy hematopoietic stem cells (HSCs) [3,11,19,20].
SPM-2 was therefore designed for a preferential elimin-
ation of AML-LSCs in vivo. It is still unknown whether this
objective can be reached because the agent has still not
been tested in humans. It is important to eliminate not
only bulk AML cells, but also the LSCs, because the LSCs
are believed to be the relevant subset within the population
of minimal residual disease (MRD) cells, which are respon-
sible for relapse and poor disease outcome [4,21-23].
New agents intended to induce a deeper remission and to
prolong the time to relapse must therefore make a deliberate
effort to target the MRD cells. Currently available chemo-
therapeutic agents achieving remission for many AML
patients probably also act (at least in part) through
the elimination of some LSCs. However, most often
they do not achieve long-lasting complete remissions
and have not been designed with the intent to specifically
eliminate MRD cells but rather bulk AML cells. A
well-defined immunophenotype of MRD cells is not
available, which would lend itself as a specific address
for the design of antibody-derived agents. However, in
a retrospective clinical study the MRD cell compartment
responsible for early relapse was tentatively equated with
the CD34+ CD38- CD123+ subset of AML cells [24]. If
these results can be confirmed by prospective studies,
then triplebody SPM-2 could be especially promising for
the therapeutic removal of AML-MRD cells. Its ability to
reach this objective critically hinges upon the availability
of sufficient numbers of active NKs in AML patients at
the time of the intended use of the agent.
The compartment of functional NKs is often reduced in
AML patients [25-29]. This impairment has been attributed
to different causes, among them a down-regulated cell
surface expression of the activating natural cytotoxicity
receptors (NCRs) NKp30, NKp44 and NKp46 [25-27,29,30].
Low-level expression of NCRs (NCRdim) on patient-derived
NKs was correlated with poor prognosis in AML, as
patients with NCRdim NKs had significantly lower 5-year
survival rates than matched patients with NCRbright NKs
[26]. Deficiencies in cytokine release have also been linked
to an impairment of NK cell function in AML patients. The
capacity of NKs to secrete IFN-gamma was highly impaired
in AML patients and was correlated with suppressed
immune responses against autologous leukemic cells
[31-33]. Finally, in adult acute leukemia, impaired
production of cytokines by NKs was associated with
early relapse [34].
Triplebody SPM-2 was not designed as a frontline
therapeutic for the initial debulking of AML blasts.
This objective is reached in most cases by the initial
chemotherapy. Rather, SPM-2 was designed to be used
after chemotherapy when the blast titer is greatly reduced
for most patients and when the titer of functional NKs is
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normal levels [28]. Therefore, here we studied the effective-
ness of SPM-2 to mediate lysis of an AML patient’s BM
blasts as targets, in combination with autologous NKs
drawn from peripheral blood at diagnosis and in remission.
The analysis was performed in comparison with NKs
isolated from the patient’s healthy monozygotic twin.
This exceptional situation provided us with a unique
opportunity to compare the activity of the patient’s
NKs with NKs genetically as closely identical as possible
from a healthy donor.
Here the patients NKs, drawn in remission, were
restored to titers in the blood comparable to those of
the healthy twin and were able to achieve effective lysis
of autologous AML blasts in conjunction with SPM-2.
Notably, they also achieved comparably effective lysis of
an established lymphoma-derived target cell line mediated
by the reference antibody RituximabTM, and had similar
expression profiles of NCRs as the healthy sibling’s cells.
The present study provides a precedent case in support of
our hypothesis that SPM-2, administered at appropriate
stages in the course of a standard therapy for AML, will
become useful as an adjuvant drug.
Methods
Expression in mammalian cells, purification and
protein-chemical characterization of triplebody SPM-2
The DNA construct coding for SPM-2 was based on the
published triplebody 123-16-33 [8] and was synthesized by
a commercial provider (Eurofins/MWG-Operon, Ebersberg;
Germany). The CD16-specific scFv was stabilized following
published procedures [8,35] and humanized. Humanization
of the CD123- and CD33-specific scFvs and the stabilization
of the CD123-specific scFv followed similar procedures
(S. Wildenhain, I. Schubert, A. Honegger et. al., unpublished
data). The N- and C-terminal CD33- and CD123-specific
scFvs were separated from the central CD16-specific scFv
by (G4S)x4 linkers. For expression purposes, human 293 F
cells (DSMZ; German Collection of Microorganisms and
Cell Lines; Braunschweig, Germany) were stably transfected
with plasmid DNA using the 293fectinTM transfection re-
agent (Life Technologies, Darmstadt, Germany) according
to the manufacturer’s instructions in a total volume of
30 ml. The cells were then cultured under continuous
selection with hygromycin C. The recombinant protein
was captured from culture supernatants via its C-terminal
hexahistidine tag by retention on a metal-ion affinity
matrix and purified by anion- and cation-exchange chro-
matography. Concentrations of the purified protein were
determined by spectrophotometry and calculated using
the molar extinction coefficient derived from the amino
acid sequence. The resulting final protein meets current
regulatory standards and industry norms, and was named
SPM-2 to indicate its status as a candidate for clinicaldevelopment. Equilibrium binding constants (KD) of each
of the individual scFvs of SPM-2 were in the 20–30 nM
range, and thus were similar to the values reported for the
initial agent [8].
Preparation of primary cells from blood and bone
marrow of human donors
Peripheral blood and bone marrow samples were drawn
from subjects into EDTA solution after receiving informed
consent. The project was approved by the Ethics Committee
of the University of Munich Medical Center. Bone marrow
mononuclear cells (BMMC) containing the leukemic
blasts and Peripheral Blood Mononuclear Cells (PBMCs)
were enriched by ficoll density centrifugation using the
Lymphoflot reagent (Biotest, Dreieich, Germany) according
to manufacturer’s instructions. Isolated cells were then
either suspended in RPMI medium (Life Technologies)
containing 10% fetal bovine serum (FBS) with penicillin
and streptomycin (PS) at 100 units/ml and 100 μg/ml,
respectively, for immediate use, or stored frozen in a
solution containing 90% FBS and 10% DMSO for future
use. Cell viability was assessed by trypan blue exclusion.
Ex vivo expansion of MNCs from healthy donors in the
presence of IL-2
PBMCs were expanded ex vivo in RPMI medium
containing Interleukin-2 (IL-2) plus 5% human serum
(Life Technologies) for 20 days as described [16,36],
and were then frozen in aliquots for subsequent use.
Prior to use in cytolysis experiments, the cells were
thawed and cultured overnight in RPMI medium
containing 5% human serum plus 50 units/ml and
50 μg/ml PS, respectively, but no additional IL-2.
Flow cytometric analysis
Flow cytometric analysis was performed with an Accuri
C6 flow cytometer (BD Biosciences, Heidelberg, Germany).
The CD3-, CD16-, and CD56-specific monoclonal anti-
bodies (mAbs) used for the analysis of NK cell content in
PBMC-preparations as well as isotype control mAbs were
from Immunotech (Marseille, France), while the NKp30-,
NKp44-, NKp46-specific and isotype control mAbs used
for the analysis of NK cell receptors (NCRs) [37] on iso-
lated NKs were from eBioscience (Frankfurt, Germany).
Cell surface densities of CD33 and CD123 were measured
using a calibrated cytofluorimetric assay as described
[8,35]. For this purpose, a commercial kit of fluorescent
beads with known numbers of fluorescent chromophores
per bead (QIFIKIT®; DAKO; Hamburg, Germany) was
employed, as well as fluorescent-labeled mAbs. This pro-
cedure allows the investigator to express the measured
fluorescent intensity of mAbs bound to the surface of the
patient’s cells in terms of average number of antigen copies
per cell [38].
Figure 1 Structure of single chain triplebody SPM-2. ScFv
domains (colored in the diagram) specific for CD33, CD16 and
CD123, respectively, were connected by two (Gly4Ser)x4 linkers
(black lines) into a single polypeptide chain. The distal scFv domains
specific for CD33 (orange) and CD123 (green), bind targets on the
same AML blast while the central scFv domain (blue) binds CD16 on
NK cells. Antigen binding sites are indicated by the triangular pockets.
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Redirected Lysis (RDL) assays using Calcein release
In this study we refer to cell-mediated cytolysis assays
with whole antibodies as “ADCC” and to tests with
antibody-derived agents such as triplebodies as “redirected
lysis (RDL)” assays. Non-radioactive cytolysis assays based
on the release of calcein from target cells pre-labeled with
calcein AM (Life Technologies) were performed as
described [16,39]. The cytolytic activity of NKs from
various sources was calibrated in standard ADCC assays
with the commercial CD20-mAb RituximabTM [39,40] as
the mediator of lysis and lymphoma-derived Raji cells [41]
as targets. This calibration allowed us to assess the
cytolytic activity of NKs from various sources using a
standard mAb and a commonly used target cell line, and
thus to make our results comparable to the current
benchmarks in the field. For the calibration reaction with
RituximabTM, untouched NKs were first enriched by the
MACS kit (Miltenyi kit; see above) from PBMC samples
and then used at a constant effector-to-target (E : T) ratio
of 2.5 : 1 against Raji targets. The same NKs were also
used in redirected lysis experiments with the patient’s autolo-
gous bone marrow AML blasts as targets in conjunction
with SPM-2. Specific lysis was measured by quantitating the
release of calcein from target cells using a fluorimeter/ELISA
plate reader and expressed in relative light units (RLU) at
485/535 nm. Calcein release was measured at 3 and 4 hour
time points for ADCC and RDL experiments, respect-
ively. Specific cellular cytotoxicity was expressed as
overall lysis minus the background of spontaneous
lysis mediated by the NKs alone, in the absence of
added antibody-reagents. Specific lysis was evaluated
by the formula:
% specific lysis = 100 * (Experimental Release RLU –
Background Release RLU)/(Maximal Release RLU –
Background RLU).
Enrichment of human NK cells by preparative sorting
with immunomagnetic beads
NKs were enriched by negative selection using a
commercial NK cell isolation kit (Miltenyi Biotec MACS
sorting kit, Bergisch Gladbach, Germany) according to
manufacturer’s instructions. The enriched cells are
referred to as “untouched” NKs, because as a result of
the negative selection, no residual mAb is bound to
their surface and they have not been eluted from an
affinity matrix with harsh reagents. Starting material
were ficoll-hypaque purified PBMCs from blood sam-
ples of the donors. The enriched NKs were then either
resuspended in RPMI medium containing 10% FBS
with PS at 100 units/ml and 100 μg/ml, respectively, for
use in ADCC and RDL assays, or placed in PBS solution
containing 1% bovine serum albumin (BSA) for flow
cytometric analysis.Measurement of IFN-gamma and TNF-alpha release into
peripheral blood samples by ELISA assays
Concentrations of human cytokines IFN-gamma and
TNF-alpha were measured with ELISA kits (eBioscience)
following manufacturer’s instructions. Triplebody SPM-2
was added to peripheral blood samples at concentrations
of 10, 1, or 0.1 nM , and the reaction mixtures were then
cultured for 6 h at 37°C in 96 well round bottom Nunc
plates in 200 ul volumes. Blood samples were frozen and
stored at −20°C and were thawed only immediately
before use in cytokine assays. In addition, cytokine release
was studied with the same ELISA kits in supernatants
from the 4 h RDL and 3 h ADCC assays, in which
MACS-purified NKs had been used as effectors against
autologous BM blasts as targets.
Statistics
All statistical analysis was performed by STATVIEW 4.5
programs from Abacus Concepts (Berkeley, CA) using
Student’s t-test for the final determination of significance
(p < 0.05).
Results
SPM-2 mediates efficient lysis of BM leukemic blasts from
a patient with FAB M1 AML in conjunction with effector
cells from a healthy unrelated donor
To evaluate the ability of SPM-2 (Figure 1) to mediate
lysis of blasts from a patient diagnosed with an AML
FAB M1, RDL experiments were performed with isolated
BMMCs obtained from the patient at diagnosis as targets.
The BMMCs prepared in this manner contained 89.7%
AML blasts, as determined by morphology and cytological
criteria (Table 1). Five hundred million (5 x 108) MNCs
were recovered from a 5 ml BM sample of this patient,
Table 1 Data and immunophenotype of AML FAB-M1 patient BMMCs
Gender Female
Age: 21 years old
Diagnosed with: AML FAB-M1; AML without maturation according to WHO classification [42]
Blast titer: 89.7% blast in the marrow at diagnosis
Case history One course of induction chemotherapy following HAM protocol
high dose cytarabine with mitoxantrone [49]
Current status: Complete remission acheived by induction chemotherapy (HAM)
Myeloid cells % (in blast gate) Co-expression (cross-lineage) % (in blast gate)
CD 34 89.6% CD34/CD56 47.9%
CD 33 <19% CD34/CD7 12.3%
CD 123 n.d. at diagnosis CD34/HLA-DR 90.5%




Cy MPO cytoplasmic myeloperoxidase; flourescent marker enzyme for the myeloid lineage.
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for further analysis.
Among the isolated BMMCs, 89.6% expressed detectable
levels of CD34, consistent with the diagnosis of a FAB M1
AML. The FAB M1 AML subtype commonly displays very
immature blasts and a high percentage of CD34-positive
cells. It is called “AML without maturation” in the WHO
classification [42] and often leads to low white blood cell
counts. At diagnosis less than 1% of the BMMCs expressed
cell surface CD33, leading to the initial diagnosis of a
“CD33-negative AML”. Expression data for CD123 at
diagnosis are not available. Subsequent cytofluorimetric
analysis gated on the BMMC population (consisting of
approx. 90% AML blasts) performed under more sensitive
conditions (calibrated cytofluorimetry; Figure 2A) revealed
a mean expression of 130 and 230 copies per cell of
CD33 and CD123, respectively, in this population of cells.
These are very low levels, considering that blasts from
other AML subtypes can commonly carry up to several
thousand and sometimes several ten-thousand copies per
cell of these antigens [8,43,44].
This patient’s AML blasts were lysed efficiently by
SPM-2 in combination with MNCs expanded ex vivo for
20 days with IL-2 from a healthy unrelated donor used
as a source of effectors (Figure 2B). Net lysis of the
targets by the effector cells alone was 15 ± 11%, net lysis
in the presence of a saturating (10 nM) dose of SPM-2
plus effectors was 80 ± 20% (Figure 2B). Thus, specific
lysis induced by the triplebody was approximately 65%.
This is a surprisingly high value for a 4 h assay, considering
the low surface density of both target antigens.
The majority of AML-LSCs are contained in the
CD34-positive subset of bone marrow cells [11,45].
Therefore we analyzed, whether SPM-2 was capable ofmediating lysis of this subset, as a first step towards
answering the key question, whether SPM-2 can mediate
lysis of AML-LSCs. As a result, in a 4 h RDL-reaction using
isolated AML BMMCs as targets and ex vivo expanded
MNCs from an unrelated donor as effectors, SPM-2
mediated a significant reduction of the CD34-expressing
subset to 15%, down from 89.6% at the start of the reaction
(Figure 2C, right panel). Exposure to the MNC effectors
alone reduced the CD34-positive blasts down to only 62%
(Figure 2C, left panel). Thus, the net effect of treatment
with SPM-2 was a specific depletion of the CD34-bearing
cells by 47%.
Beyond the CD34-positive compartment, the majority
of AML-LSCs are typically found in the CD34pos
CD38neg subset, although some LSCs are also present in
other cellular subsets [19]. Moreover, the AML MRD
cells relevant for relapsed disease have been reported to
be predominantly contained in the CD34pos CD38neg
CD123pos compartment [24]. Therefore, in an attempt to
determine, whether SPM-2 was capable of eliminating
AML-MRD cells in a narrower cellular subset beyond
the broader CD34pos compartment, we analyzed whether
SPM-2 also affected the CD34pos CD38neg CD123pos
subset within the AML BMMC sample in combination
with IL-2 expanded effector cells from a healthy donor.
The experiment was performed using a similar 4-color
flow cytometric analysis as reported by others [24].
As an initial result, obtained with limited numbers of cells,
depletion of the CD34pos CD38neg CD123pos subset was
observed following treatment with SPM-2 plus allogeneic
effectors in comparison to treatment with MNCs alone
(data not shown). For this patient, the CD34pos CD38neg
cells represented approximately 1.4% of the total BMMCs.
This value falls into the typical range reported for this subset
Figure 2 (See legend on next page.)
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Figure 2 BM blasts from an FAB M1 AML patient are lysed efficiently in a RDL reaction by effectors from an unrelated donor,
mediated by SPM-2. (A) Patient isolated BMMC were stained with fluorescent antibodies specific for CD33 and CD123, respectively, in
comparison to isotype controls. P2: gate used for analysis of live BMMCs allowing their discrimination from dead cells. Mean fluorescence
Intensities measured for each antigen were converted to antigen densities by calibrating fluorescence intensities with the QuiFi kit (Methods).
(B) MNCs from an unrelated healthy donor, expanded ex vivo in the presence of IL-2 (Methods), were used as effectors at an MNC : target (E:T)
ratio of 10 : 1 in a 4 h RDL assay. This corresponds to an E:T ratio of NK cells : targets of 2.5 : 1, because NK cells were 25% of all cells in this
expanded MNC population. Targets were BMMCs from the AML patient obtained at diagnosis, pre-labeled with calcein AM. SPM-2 was added
at 10 nM concentration (right bar). The control reaction was allowed to proceed without added agents (left bar; NKs alone). Cellular lysis was
measured by calcein release and plotted as fraction (%) of maximum release. Error bars: arithmetic means over 3 separate experiments (n = 3).
(C) Flow cytometric analysis after an RDL reaction. Patient’s BMMCs were treated with effector cells and SPM-2 in a 4 h RDL experiment as in
panel A. At the end of the reaction, cells were stained with a fluorescent-labeled CD34-specific mAb and analyzed by FACS. Numbers of CD34pos
cells are plotted against the intensity of CD34-specific fluorescence. Left panel: after reaction with effectors alone; right panel: after reaction with
effectors plus SPM-2. Numbers in upper right corner: percent of CD34pos cells surviving at the end of the reaction.
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provides a first indication in favor of our contention that
SPM-2 is capable of eliminating cellular subsets enriched in
AML-LSCs and MRD cells through the recruitment of
activated NKs. While this result is consistent with the claim
that SPM-2 can eliminate LSCs, definitive proof requires
further and more stringent analysis than we were able to
perform here due to the scarcity of this BMMC sample.
Cytolytic activity of patient’s NKs drawn at diagnosis and
in remission compared with NKs from a healthy
monozygotic twin
Next, we wished to determine whether SPM-2 was capable
of mediating lysis of the patient’s AML blasts by autologous
NKs. For this patient, we had the rare opportunity to
obtain NKs from peripheral blood both at diagnosis
and in remission after completion of the induction
chemotherapy, and to compare their titers and cytolytic
activities to NKs isolated from a healthy monozygotic twin.
As a result, MACS-purified NKs drawn from the sibling
and the patient in remission showed similar cytolytic
activity mediated by SPM-2 towards the patient’s AML
blasts (Figure 3A, red). Mean specific lysis obtained with
NKs from the sibling was 47 ± 7% versus 37 ± 2% for NKs
from the patient in remission. These values are arithmetic
means over 3 independent experiments (n = 3). By
contrast, the cytolytic activity of the NKs drawn from
the patient at diagnosis was significantly lower. With equal
numbers of effector cells used as an input for each reaction,
only 4.3 ± 2.6% specific lysis was observed with a saturating
dose of SPM-2 (10 nM; Figure 3A, left bar).
Finally, we wished to determine whether these com-
parable activities of the patient’s and sibling’s NKs were
only observed with the patient’s AML blasts as targets,
or whether this was an intrinsic property of these NKs,
also observed for other targets. Therefore, a benchmark
ADCC experiment was performed with CD20-positive Raji
lymphoma-derived cells as targets (Figure 3B, blue), the
commercial CD20 antibody RituximabTM as the thera-
peutic agent, and with immunomagnetically purifiedNKs as effectors. As a result, comparable lytic activity
was found again for NKs from the patient in remission
and the twin (Figure 3B). Here, NKs from the patient in
remission produced 26 ± 4% specific lysis using a standard
dose of RituximabTM compared to 25 ± 8% for the sibling’s
NKs. NKs from the patient at diagnosis also produced
lower specific lysis in this assay (4 ± 2%).
Taken together, these results indicate that the peripheral
blood NKs from the patient in remission are comparable
in cytolytic activity to those of the healthy twin in response
to SPM-2. One needs to bear in mind, however, that
this patient was younger than the average AML patient at
diagnosis and that response to therapy is usually better for
younger patients.
Titers of AML blasts and NK cells in peripheral blood at
diagnosis and in remission
To look for explanations for the apparent deficiency in
cytolytic activity of the NKs from the patient at diagnosis,
frequencies of NKs and leukemic blasts in the various
PBMC samples were assessed by flow cytometry (Figure 4).
Plots of side scatter (SSC) vs. fluorescence intensity of
cells stained with a FITC-labeled CD45 mAb revealed a
well-defined population of CD45-FITCdim x SSClow cells
(P1 in Figure 4A). These cells have been identified as
AML blasts by other authors [24,46]. Among the patient’s
PBMCs drawn at diagnosis, this subset was abundant
(58%; Figure 4A, left panel), while it accounted for only
about 1% of all PBMCs from the patient in remission and
the healthy twin (Figure 4A, central and right panels).
NKs were identified in cytofluorimetric studies as
CD16posCD56pos cells (Figure 4B). Only 1% of the patient’s
PBMCs at diagnosis fell into this gate (Figure 4B, left panel),
whereas 6.3 and 7.7% of all PBMCs had this phenotype for
the patient in remission and the healthy sibling (Figure 4B,
central and right panels). This finding supports our initial
expectation that for an AML patient in remission the NK
cell compartment should be restored to almost normal
levels. It also is the most likely explanation for the results





































Figure 3 NK cells from PBMCs of the patient in remission and
the healthy twin have comparable cytolytic activity. (A) MACS
sorted NKs isolated from PBMCs of the patient drawn at diagnosis
(left bar), in remission (central bar) and from the healthy twin (right bar)
were used in RDL assays against calcein labeled BMMCs from the
patient at diagnosis as targets (red). 4 h RDL reactions were run at an
E : T ratio of 2.5 : 1 and incubated with a 10 nM dose of SPM-2 versus
NKs alone as control. Error bars: arithmetic means over 3 separate
experiments (n = 3). (B) The same NK effector populations as in panel A
were also used in 3 h ADCC reactions at the same E : T ratios. Target cells
were calcein labeled Raji cells (CD20pos). Reactions mediated by
10 μg/ml (approx. 70 nM) of the commercial CD20-antibody RituximabTM
(blue). Error bars: arithmetic means over 3 separate experiments (n = 3).
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and RDL assays than the corresponding cells from the
patient in remission and her healthy twin. These data
suggest that the deficiency in cytolytic function observed at
diagnosis most likely was due to reduced NK cell titers.
Interestingly, a high percentage of CD56bright CD16low
cells were found in PBMCs of the patient at diagnosis
(Figure 4B, left panel, upper left quadrant). This populationhas previously been reported by other authors to be
increased in AML patients and has been described as a
characteristic NK cell subset with elevated production of
cytokines [30]. This result is consistent with the diagnosis
of this patient showing an unusually high percentage of
CD34posCD56pos cross-lineage cells amongst the AML
blasts (47.9% of blasts; Table 1).
Enrichment of NK cells by MACS sorting and titers of
T cells in PBMCs
After preparative enrichment by MACS sorting,
CD56brightCD16bright NKs accounted still for only 1.4%
of total cells in the sample from the patient at diagnosis
(Figure 5A, left). This poor enrichment probably reflects
the high content of AML blasts with very immature,
early progenitor phenotype, devoid of lineage markers,
in the PBMC sample taken at diagnosis. Therefore, negative
sorting using antibodies specific for lineage markers did
not remove these cells. In contrast, the MACS-enriched
CD56brightCD16bright NKs accounted for approx. 77% of all
cells in the corresponding samples from the patient in
remission and the healthy twin used in the RDL and
ADCC assays (Figure 5A; central and right panels). These
observations are consistent with previously reported
decreased frequencies of NKs in the blood of AML
patients [30].
Finally, an approximate 10-fold reduction of the T cell
compartment was also observed comparing PBMCs
from this patient drawn at diagnosis with those obtained
in remission and those from the healthy twin (Figure 5B).
Only 6.9% of the patient’s PBMCs drawn at diagnosis
were CD56negCD3pos T cells, compared with 65.2% and
78.7%, respectively, for the cells from the patient in
remission and the healthy twin. This finding indicates
that in the remission stage after the initial chemotherapy,
not only NKs are restored but also the T cell compartment
recovered to approximately normal levels.
Expression levels of natural cytotoxicity receptors (NCRs)
in PBMC samples
As impaired cytolytic activity of NKs from AML patients
had been proposed to be caused by reduced expression
of NCRs [25,26], expression of NKp30, NKp44 and
NKp46 on enriched NKs was studied (Figure 6). No
significant difference in the expression patterns was
observed between MACS enriched NKs from the patient
in remission versus the healthy sibling (Figure 6A). The
corresponding analysis for NKs from the patient at
diagnosis was rendered more difficult by the fact that
NKs were of low abundance in the MACS-enriched
sample at this time. This analysis was therefore refined
by further gating for CD16pos cells and then analyzing
the NCRs on this gated population of NKs. In this
manner, an essentially unchanged NCR expression profile
Figure 4 Analysis of AML blasts and NKs within PBMCs from the different donor samples. (A) Blast content among PBMCs from the
patient at diagnosis and in remission (left and central panels) or from the healthy twin (right) is shown. PBMCs were stained with a FITC-labeled
CD45 mAb and analyzed against side scatter (SSC) by flow cytometry. CD45dim x SSCLOW cells have been defined as AML blasts [24]. Dashed line:
P1 gate (blasts). Numbers in the corners of quadrants: fraction of total cells falling into this quadrant. (B) Analysis of NK cell content. PBMCs form
the same sources as in A were stained with FITC-labeled CD16 and PE-labeled CD56 mAbs. NKs were defined as CD16posCD56pos cells (upper
right quadrant). The population in the upper left corner in the left panel is the unusual population of CD56brightCD16neg cells, previously reported
in AML samples [30] as an NK subset that exclusively produces cytokines.
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strategy used for this analysis of the PBMC sample drawn
at diagnosis is shown in Figure 6C. From these combined
observations, we conclude that for this particular patient
the NCR expression profiles remained unchanged and
that changes in the levels of NCRs are unlikely to be the
cause of the impaired cytolytic functions recorded here.
Whole blood samples from the AML-patient and the
healthy sibling show different levels of cytokine release
after addition of SPM-2
Reduced cytokine (IFN-gamma) release by NKs from
AML patients had been reported to be correlated with
suppressed immune responses against autologous leukemic
cells [32,33,45]. Therefore, we tested whether differences in
cytokine release were detectable after addition of SPM-2
either to whole blood samples from the patient drawn at
diagnosis or those from the patient in remission and the
twin. Determinations of IFN-gamma release by ELISAproduced no signal above the detection threshold (4 pg/ml).
However, TNF-alpha was detected in the corresponding
samples after addition of SPM-2 (Figure 7A). Following
incubation for 6 h with a saturating dose of SPM-2
(10 nM), 4.7 ± 0.1 pg/ml of TNF-alpha were detected
in blood from the healthy sibling versus only 1.1 ± 0.1 pg/ml
in the patient’s sample drawn in remission (Figure 7A).
Thus, whole blood cells from the patient in remission
showed a reduced release of TNF-alpha in response to the
addition of SPM-2, compared to cells from the healthy
sibling. This differential cytokine response does not appear
to have affected the cytolytic activity mediated by SPM-2, as
these two sources of NKs did not show major differences in
our RDL and ADCC assays with autologous and allogeneic
leukemic cells as targets.
To investigate, whether cytokine release during cytolytic
reactions with MACS-purified NKs from these different
sources was similarly independent of target antigen and
the type of target cell line, we analyzed the cytokine
Figure 5 Analysis of MACS sorted NKs and T cells within PBMCs isolated from the different donor samples. (A) The CD16posCD56pos
NK cells enriched by immunomagnetic beads (MACS; Methods) are shown in the upper right quadrant. Events in the lower left quadrant in the
sample from the patient at diagnosis are considered to be very immature blasts devoid of lineage markers as discussed in the text. (B) CD3pos
CD56neg cells (lower right quadrant): T cells.
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by assaying the supernatants of these reactions in our
ELISA assay (Figure 7B and C). TNF-alpha production
was reduced for the reaction with NKs from the patient in
remission relative to the healthy sibling but even more so
with NKs from the patient at diagnosis. This result was
observed for the supernatants from both the ADCC and
RDL assays. IFN-gamma release was undetectable. These
results are consistent with previous reports indicating that
NKs from AML patients are attenuated in their release of
cytokines [27,29].
Discussion
The most important result of this study is that it helped
to dispel concerns raised by critics about the use of
triplebodies for the treatment of AML, because they rely
on NK cells as effectors. The main argument was that
too few NK cells were present in an AML patient for
triplebodies to be effective. The critics held that it would
be preferable to recruit T cells rather than NK cells as
effectors, because T cells were present in greater numbers,
because they have higher intrinsic cytolytic activity,are capable of serial lysis of several target cells in a
consecutive manner, and can be stimulated to proliferate
as a result of exposure to the agent. We cannot address all
of these points here in detail, and some of our arguments
regarding the relative merits of recruiting NK cells vs.
T cells have been reviewed elsewhere [17]. Suffice it to
state that NKs are also capable of serial lysis and that their
numbers can be increased in patients after treatment with
antibody-derived agents recruiting NKs as effectors [28,47].
Therefore, after clinical administration of agents related to
SPM-2 such as the tandem diabody AFM-13 specific for
CD30 and CD16, NKs can expand in human recipients
in vivo, and sufficient numbers can become available for
therapeutic effects, even for malignancies such as Hodgkin
Lymphoma that include semi-solid tumor masses [47].
Our results presented above (Figure 5B) suggest that
for the patient of the present study, CD3-positive T cells
were also greatly reduced in peripheral blood at diagnosis
and only recovered together with other leukocytes in the
remission phase. Finally, it is not known how many T cells
and how many NKs are needed for an effective therapy
with such agents. The absolute numbers of NK cells in
AB
C
PBMC Gate CB16 Gate
Figure 6 Unaltered expression patterns of the NCRs NKp30, NKp44 and NKp46 on enriched NKs from the patient at diagnosis, in
remission and the healthy twin. (A) Expression pattern of NCRs on enriched NKs from the patient in remission (red) and the healthy twin (blue)
compared with cells stained with an isotype control mAb (black). (B) To analyze NCR expression on enriched NKs from the patient at diagnosis,
an additional sorting step for CD16 positive cells was performed to focus the analysis on the small subpopulation of NKs. NKs from the patient at
diagnosis (red) are compared with cells stained with an isotype control mAb (black). (C) Gates chosen to generate data shown in panels A) and
B). Left: gate chosen to identify MACS-sorted cells (negative selection for NK cells). Right: additional gate used for identification of the CD16 pos
subset (lower right quadrant) of the MACS sorted cells from the patient sample obtained at diagnosis (Methods).
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http://www.translational-medicine.com/content/11/1/289remission (Figure 4B) may be lower than those of T cells,
although absolute numbers have not been determined, but
even lower numbers of NKs may be sufficient for therapeutic
success.In the present study, the patient’s NK cells were
greatly reduced in relative abundance. At diagnosis their
frequency was at least 6–7 fold reduced compared to the




































































Figure 7 Secretion of TNF-alpha from whole blood or from
supernatants of cytolysis reactions after treatment with SPM-2.
(A) Release of TNF-alpha into whole EDTA treated blood from the
patient in remission versus the healthy twin after addition of SPM-2.
200 μl samples of EDTA-blood were incubated for 6 h at 37°C with a
10 nM dose of SPM-2. Secretion of TNF-alpha was measured with a
commercial ELISA kit (Methods). (B) Supernatants from a 4 h RDL
assay using 10 nM dose of SPM-2 and the patient’s autologous BMMCs
drawn at diagnosis as targets (red). Effector cells were MACs enriched
NKs isolated from PBMCs taken from the patient at diagnosis (left), in
remission (center), or from the healthy sibling (right). Secreted
TNF-alpha was measured as in panel A. Plotted data are the
arithmetic means over 6 independent experiments (n = 6). Error bars
represent the standard error of the mean (SEM). Statistical significance
was reached with p = .002 (*) and .004 (**) for the differences between
cells from the healthy twin and the patient in remission versus
at diagnosis, respectively. (C) Supernatants from a 3 h ADCC assay using
10 μg/ml dose of Rituximab and Raji leukemia cells as targets were
assayed for TNF-alpha secretion using the same NK effector populations
as for panel A (blue). Plotted data are mean values over six independent
experiments (n = 6). Statistical significance was reached with p = .0001
(*) and .0003 (**), for the differences between healthy twin and patient
in remission versus at diagnosis, respectively.
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normal numbers of NKs with typical cytolytic activity
were found. This observation is important for us because
SPM-2 was not designed to debulk the mass of leukemic
blasts as a frontline agent. Instead, it was designed to act
as an adjuvant to further reduce the MRD pool after an
initial induction chemotherapy and thus to achieve
deeper and longer-lasting remissions.
In this context, the observation that not only the
total population of AML blasts from this patient was
efficiently lysed by SPM-2 together with MNC effectors
(Figure 2B), but that the CD34pos subset was also specifically
reduced (Figure 2C), is encouraging. This finding opens the
possibility that the AML-LSCs contained within the CD34
compartment were also affected by this treatment. If this
were true more generally beyond this single patient, then this
would be a welcome result, because AML-LSCs are reported
to have increased resistance to treatment with standard
chemotherapeutic agents [19,48]. AML-LSCs are typically
contained in the CD34pos compartment, and if the LSCs of
this patient were similarly sensitive towards cytolysis
mediated by SPM-2 in conjunction with NKs as the
overall population of CD34pos cells, then this would
suggest, that SPM-2 may become a useful new agent
for the removal of LSCs. However, these extrapolations
are made with due caution, because the AML-LSCs may
only account for a minor subset of all CD34pos blasts in
this patient and therefore may have escaped lysis in our
experiments.
We were further encouraged by our preliminary finding
reported here that SPM-2 mediated specific lysis of the
CD34posCD38neg CD123pos subset contained within the
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confines the relevant MRD cells than the broader CD34pos
compartment. Admittedly, this was only a single initial
experiment and further confirmation is needed. Yet, the
results obtained so far suggest that SPM-2 in conjunction
with functional NKs was capable of effectively eliminating
the CD34posCD38neg CD123pos subset, reported by others
[24] to include the MRD cells.
No major changes were observed here in the expression
profiles of NCRs on NKs between the samples from the
patient at diagnosis and in remission, and both profiles
were similar to those observed for the healthy sibling. This
result was somewhat surprising, because it had been
reported by others that differences in NCR expression
profiles could be a major cause for impaired functional
activity of NKs from AML patients [25-27,29]. One
possible explanation for our result is that the expression
profile of this particular patient is unique and differs from
those of the majority of patients reported elsewhere.
Another possible explanation is that in the cases published
by others, NCR expression levels were generally compared
between NKs from AML patients and those from
unrelated healthy donors. This comparison may be less
informative than the more rigorous comparison reported
here, because it is not excluded that patients in the
published studies expressed lower intrinsic NCR levels
than the average healthy donor, and that this reduced
expression may even have been a cofactor predisposing
them to the development of the disease.
Conclusions
Titers of peripheral blood NKs from a FAB M1 AML
patient had recovered to normal levels in remission after
induction chemotherapy, and these cells showed normal
functional activity in cytolytic assays mediated by the
therapeutic triplebody SPM-2. Comparable cytolytic
activity of NKs from the patient in remission and a healthy
twin were observed both for the patients autologous
leukemic blasts as targets, and in benchmark experiments
with the standard antibody RituximabTM against Raji
lymphoma cells as targets. The functional impairment
of this patient’s NKs obtained at diagnosis probably is
not caused by an altered expression pattern of the
NCRs, NKp30, NKp40 and NKp46, as suggested in the
literature. Expression profiles of these receptors were
unaltered in our case. The major cause for a func-
tional impairment of the patients NK cell response at
diagnosis appears to be the result of a reduced NK
cell titer. Overall, our results indicate that a useful
time point to administer SPM-2 for the treatment of
AML patients will be the remission phase after induc-
tion chemotherapy when blast titers are reduced and
titers and functional activity of normal leukocytes have
recovered.Abbreviations
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